Live tape
Top 8, mentions 7d10,662TSLA2,471 mentions▲ +0.06SPCX2,006 mentions▲ +0.08GOOGL1,333 mentions▲ +0.04CRWV1,192 mentions▲ +0.04NVDA1,061 mentions▲ +0.07QQQ1,025 mentions▲ +0.05META805 mentions▲ +0.05NBIS769 mentions▲ +0.07

Equity · Healthcare

LGND

NASDAQ

Ligand Pharmaceuticals (LGND)

$289 +0.35% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 10, 2026
Price · Chart
24 sessions
$300 $270 7 Aug 10 Sep

The line runs $293 on 7 August through $289 on 10 September, on a scale from $270 to $300. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 24 sessions, 7 Aug – 10 Sep 2026
Market cap $5.8B
P/E (TTM) 30.0
52-week range $165 – $323
Avg volume 28.0K

as of Sep 10, 2026

Ligand Pharmaceuticals (LGND) insider trades

SEC Form 4 · last 90 days · newest reported trade 2 Oct 2026

In the 90 days to 21 Oct 2026, Ligand Pharmaceuticals insiders reported 6 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 4 Mar 2026, show no open-market purchase.

Open-market buys 0
Open-market sells 6
Net sold $16.07M
Non-trade filings 5
Date Insider Type Shares Value
02 Oct 2026 Reardon Andrew CLO & Secretary Sell 5,000 $1.52M
10 Sep 2026 Zimmermann Martine Director Sell 1,200 $342K
03 Sep 2026 Reardon Andrew CLO & Secretary Sell 5,000 $1.43M
12 Aug 2026 Espinoza Octavio Chief Financial Officer Sell 31,641 $9.24M
12 Aug 2026 Haas Jason Director Sell 7,138 $2.09M
03 Aug 2026 Reardon Andrew CLO & Secretary Sell 5,000 $1.44M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
02 Oct 2026 Reardon Andrew CLO & Secretary Option exercise 340 $18K
22 Sep 2026 Zimmermann Martine Director Tax withheld 115 $34K
12 Aug 2026 Espinoza Octavio Chief Financial Officer Option exercise 31,641 $1.80M
12 Aug 2026 Haas Jason Director Option exercise 6,138 $316K
03 Aug 2026 Reardon Andrew CLO & Secretary Option exercise 5,000 $261K

Ligand Pharmaceuticals (LGND) reported financials

SEC EDGAR XBRL SEC EDGAR

Ligand Pharmaceuticals reported revenue of $268.1M for the fiscal year ended 31 Dec 2025. Net income over the same period was $124.5M.

Figure Reported Period
Revenue $268.1M 31 Dec 2025 fiscal year
Net income $124.5M 31 Dec 2025 fiscal year
Diluted EPS $6.13 31 Dec 2025 fiscal year
Total assets $2.2B 30 Jun 2026 at period end
Total equity $967.5M 30 Jun 2026 at period end

Ligand Pharmaceuticals (LGND) earnings

SEC EDGAR

Ligand Pharmaceuticals last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $2.22; no next date is announced in SEC filings yet.

Date Period EPS Revenue
30 Jun 2026 Q2 2026 $2.22 —
31 Mar 2026 Q1 2026 −$0.67 —
31 Dec 2025 FY 2025 $6.13 —
30 Sep 2025 Q3 2025 $5.68 —
30 Jun 2025 Q2 2025 $0.24 —
31 Mar 2025 Q1 2025 −$2.21 —
31 Dec 2024 FY 2024 −$0.22 —
30 Sep 2024 Q3 2024 −$0.39 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

Ligand Pharmaceuticals (LGND) institutional holders (13F)

SEC Form 13F SEC EDGAR

5 of the 45 institutional funds we track reported a Ligand Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined $66.8M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Fisher Asset Management Held (±25%) −5.1% shares 121,440 $38.4M
D. E. Shaw & Co. Trimmed −27.9% shares 56,515 $17.9M
Two Sigma Investments New position 18,825 $6.0M
AQR Capital Management Added +40.4% shares 10,444 $3.3M
Millennium Management New position 3,975 $1.3M
Citadel Advisors Exited
Man Group Exited
Marshall Wace Exited

Ligand Pharmaceuticals (LGND) fails-to-deliver

SEC CNS data SEC

On 30 Sep 2026, 156 shares of Ligand Pharmaceuticals failed to deliver (about $48K).

Settlement date Shares failed Notional % of shares out
30 Sep 2026 156 $48K 0.001%
24 Sep 2026 546 $163K 0.003%
21 Sep 2026 94 $27K <0.001%
18 Sep 2026 219 $62K 0.001%
16 Sep 2026 54 $15K <0.001%
11 Sep 2026 2,018 $584K 0.010%

Congressional trades in Ligand Pharmaceuticals (LGND)

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in Ligand Pharmaceuticals is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 15 Jan 2026.

Date Member Type Amount
15 Jan 2026 filed 13 Feb 2026 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K

Ligand Pharmaceuticals (LGND): frequently asked questions

From live data

Have Ligand Pharmaceuticals insiders bought or sold shares recently?

In the 90 days to 21 Oct 2026, Ligand Pharmaceuticals insiders reported 6 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 4 Mar 2026, show no open-market purchase. A further 5 filings were grants, awards, gifts or exercises rather than open-market trades.

How many institutions hold Ligand Pharmaceuticals?

5 of the 45 institutional funds we track reported a Ligand Pharmaceuticals position for the quarter ended 30 Jun 2026, per SEC Form 13F filings.

Has Ligand Pharmaceuticals had fails-to-deliver recently?

Yes. The most recent SEC fails-to-deliver record for Ligand Pharmaceuticals is dated 30 Sep 2026, when 156 shares failed to deliver.

When did Ligand Pharmaceuticals last report earnings?

Ligand Pharmaceuticals last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $2.22; no next date is announced in SEC filings yet.

What exchange is Ligand Pharmaceuticals listed on?

Ligand Pharmaceuticals trades on NASDAQ under the ticker LGND.

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARValuation computed from SEC EDGAR filings